drugset
drugset / Trial / NCT04029038

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

NCT04029038 ↗

Phase 1/2 Withdrawn M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma that has come back (recurrent) or does not respond to treatment (refractory). T-cells are collected from the patient and genetic materials called "chimeric antigen receptors (CAR)" are transferred to the collected T-cells. The CAR T-cells are then infused back to the patient's body. Giving CD19- CD22 CAR T cells after chemotherapy may help to control the disease.

Timeline

Start
2019-05-15
Primary completion
2022-11-16
Completion
2022-11-16

Outcome

Outcome not reported

Stopped (Enrollment): “0 participant accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous CD19/CD22 Chimeric Antigen Receptor T-cells Cell therapy — Intravenous
Background Cyclophosphamide Other / unclassified — Intravenous
Background Fludarabine Small molecule — Intravenous

Indications

B-cell acute lymphoblastic leukemia B-cell chronic lymphocytic leukemia